Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors.

MD, Hellmann; N, Bivi; B, Calderon; T, Shimizu; B, Delafontaine; ZT, Liu; AM, Szpurka; V, Copeland; FS, Hodi; S, Rottey; P, Aftimos; Y, Piao; L, Gandhi; VR, Galvao; CC, Leow; T, Doi

doi:10.1158/1078-0432.ccr-20-3716

Public

Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors.

Shared by NobleBlocks on Jan 13, 2021 • 12:00 AM UTC

Authors:

Hellmann MD

Bivi N

Calderon B

Abstract

<h4>Purpose</h4>Investigate the safety and efficacy of LY3415244, a TIM-3/PD-L1 bispecific antibody that blocks TIM-3 and PD-L1 in patients with advanced solid tumors.<h4>Patients and methods</h4>A phase I, multicenter, open-label study was conducted in patients with advanced solid tumors. Patients ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!